RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--ZenBio, Inc. announced that it has been awarded a Phase II SBIR grant to commercialize primary human peritoneal mesothelial cells. The $1.88 million award from the National Institutes of Health will fund continued optimization and commercial development of this unique tool for cancer, obesity, and type 2 diabetes research.
